MIV Therapeutics Successfully Completes Animal Feasibility Studies of Stroke-Prevention Devices.

VANCOUVER, British Columbia -- This replaces the release of earlier today, providing greater clarity on the applications of the technology discussed.

The corrected release reads:

MIV THERAPEUTICS SUCCESSFULLY COMPLETES ANIMAL FEASIBILITY STUDIES OF STROKE-PREVENTION DEVICES

POSITIVE EXPERIMENTAL RESULTS SPEED MIVT'S SAGAX SUBSIDIARY TOWARD HUMAN TRIALS OF NOVEL AORTIC EMBOLIC PROTECTION DEVICE

MIV Therapeutics, Inc. (OTCBB:MIVT), a developer of next-generation biocompatible stent coatings and drug delivery technologies, has successfully completed Phase I animal feasibility studies in sheep of two models of a novel implantable arterial filtration technology device designed to prevent strokes by diverting embolic particles flowing through the bloodstream. These two models of MIVT's unique Aortic Embolic Protection Device (AEPD) are being designed to prevent both major types of embolic strokes -- those triggered by heart surgery and catheterization, and those that occur naturally, not in connection with such procedures.

This successful first phase of the animal studies pave the way for further animal studies, and then for human clinical trials - the last major testing milestones as the Company prepares the stroke-preventing technology for FDA approval and potential commercialization. The AEPD filtration devices are being developed by wholly-owned MIVT subsidiary SagaX Medical Technologies Inc.

Both SagaX AEPD filter prototypes employ proprietary stent-based filter-deflector technology. The AEPD I prototype model is designed to be implanted temporarily in the aorta, the body's main artery, during heart surgery and heart catheterization to divert particles that might otherwise reach the brain, where they could trigger embolic strokes. The AEPD II prototype is designed to be implanted permanently to prevent the embolic strokes that occur from natural causes, such as aging.

"We fully expect that this new technology, once ready for the market, will have the capacity to save countless cardiac patients from the devastating effects of embolic stroke," said Dr. Dov Shimon, founder and CEO of SagaX, and Chief Medical Officer and Director of MIVT. "We look forward to proceeding to the next phases of animal studies, which are the next milestones in readying this technology for human trials."

Embolic particles that reach the brain are among the chief causes of strokes, which are the third-leading cause of death and the leading cause of disability in the world. AEPD is one of the latest innovations in the field of filter-based embolic protection devices and is the only filter being developed for use in the aorta.

MIVT estimates that the global market for AEPD devices could exceed $1.5 billion by 2009. The Company believes AEPD-1 will be particularly useful during invasive heart procedures such as electrophysiology, valve dilatations and valve repair through angioplasty, as well as heart operations. The permanently implanted AEPD-II is designed to find broad preventive applications.

MIV Therapeutics' CEO Alan Lindsay said he was greatly encouraged with the results. "The feasibility studies confirm earlier observations in the laboratory showing excellent efficacy and function of AEPD," he said. "This continued progress in our development of both prototypes of the AEPD is essential in our realization of the devices' full business potential in multi-billion-dollar neurovascular marketplace segments."

AEPD is one of the latest innovations in the field of filter-based embolic protection devices, and is the only filter developed for use in the aorta. Preliminary evaluation of prototype devices confirmed effectiveness of AEPD in an in-vitro model.

The AEPD I version is a self-expanding stent-based filter in the aorta, and designed for temporary application. The AEPD II prototype is a braided self-expanding stent deployed in the innominate artery, extending downwards into the aorta. This version can be implanted permanently to prevent cardioembolic stroke. Both AEPD I and AEPD II were inserted through a small catheter in the sheep's femoral artery and were passed retrogradely under fluoroscopy to the aortic arch.

"The study demonstrated excellent hemodynamics, ample X-ray visibility and easy drivability through 6 French (2.3mm)-diameter catheter," said Dr. Shimon. "Direct echocardiography demonstrated ample location and no significant flow disturbances. In addition, AEPD I is deployed, recaptured, relocated and removed using a proprietary delivery system designed to make it an ideal solution for embolic protection for heart surgery and invasive trans-catheter procedures in the heart."

The studies are being conducted at the world-renowned Hadassah University Hospital Cardiology Research Institute in Jerusalem, Israel, under the stewardship of cardiac specialists, Dr. Chaim Danenberg and Dr. Ronen Beeri.

Cardioembolism occurs spontaneously without procedures in 30% of all stroke victims. The risk factors for cardioembolic stroke include previous strokes; rhythm irregularities such as atrial fibrillation (present in 1-2% of the adult population and 7-10% of the people above 70); congenital malformations of the heart, such as patent foramen ovale (PFO); heart valve disease, and previous heart valve surgery.

About SagaX Medical Technologies, Inc.

SagaX develops a range of proprietary solutions, primarily endovascular interventional products, which decrease the likelihood of strokes and other serious complications that may result from cardiac procedures, as well as from naturally occurring Cardioembolic strokes. The Company's R&D center is located in Herzlya Israel, directed by Dr. Dov V. Shimon, M.D., a heart surgeon, the founder and CEO of SagaX Inc., and MIV Therapeutics director and Chief medical Officer. In March 2005, MIVT completed its acquisition of SagaX. One of the flagship technologies from SagaX is its Aortic Embolic Protection Device (AEPD), which employs proprietary stent based filter-deflector technology that can be used during Trans-Catheter Cardiology procedures, as well as during heart surgery, to minimize the risk of stroke.

About MIV Therapeutics, Inc.

MIV Therapeutics Inc. is developing a next generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and other implantable medical devices. The Company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction with metal stents. The Company's unique ultra-thin coating has been derived from a biocompatible material called hydroxyapatite (HAp) that during in-vivo animal trials demonstrated excellent safety and superior healing properties pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company's novel drug eluting technology provides an alternative solution to polymer-based drug eluting coatings currently in the stent market. The Company's drug eluting coating is designed to suit a broad range of implantable medical devices which may benefit from a highly customizable drug release profile. MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and supported a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of Hydroxyapatite as a drug eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council -- Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development Program. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Copyright (C) 2005 MIV Therapeutics Inc. All rights reserved.